SANA · Sana Biotechnology, Inc.
$3.16
+0.02 (+0.64%)
At close · Jul 21
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that the Company’s current capital resources may not be sufficient to fund its planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed May 11, 2026
Market Cap
$879.40M
Shares
278.29M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.16
Open$3.12
Day$3.11–3.24
52W$2.61–6.55
Avg vol 30d3.5M
Short int38.7M · 13.9% float · 9.1d
Short vol61%
Last earningsMay 8, 2025
DataFeb 2021–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.1 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−18%
below
Price vs 50-day avg
−3%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
14%
near low
Momentum
relative strength
1-month return
−6%
trailing
6-month return
−36%
trailing
YTD return
−22%
this year
Relative strength
−44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
19 of 201 funds reported for Jun 30 · net -10.7K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.91% of float · ▼ -4.9% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
201 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
EPS growth
+17%
Y/Y
Free cash flow
$-144.8M
Balance sheet
$71.9M
net cash
Quant / Vol
risk profile
Volatility
94%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−18%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
14%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
19 of 201 funds reported for Jun 30 · net -10.7K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.91% of float · ▼ -4.9% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
201 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $3 · 14%
52-wk high $7
vs 200-day avg -18%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SANA
this stock
Sana Biotechnology, Inc.
|
$879.40M | -22.4% | — | — | 13.9% |
|
ONC
BeOne Medicines Ltd.
|
$460.58B | +4.9% | +22179.2% | 937.3 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.33B | +6.3% | +46.2% | 28.6 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.79B | -12.4% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$54.72B | +4.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SANA | -11.5% | -6.0% | -36.4% | -9.5% | -22.4% |
| SPY | -0.5% | +0.5% | +7.6% | +0.2% | +9.7% |
| vs SPY | -11.0% | -6.5% | -44.0% | -9.7% | -32.1% |
Key facts
CIK
1770121
CUSIP
799566104
13F (30d)
17 filings
17 filers
Visit website
Investor relations